- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06159777
Præoperativ polyethylenglycol 3350 til minimalt invasiv urogynækologisk kirurgi
Præ- og postoperativ sammenlignet med kun postoperativ polyethylenglycol 3350 til minimalt invasiv urogynækologisk kirurgi
The goal of this clinical trial is to test the use of a laxative before surgery in women having surgery to fix pelvic prolapse that do not have constipation.
The main question it aims to answer is: Does use of a laxative before surgery lessen the discomfort of bowel movements after surgery? Participants will be asked to complete questionnaires before and after surgery. Researchers will compare using the laxative before and after surgery versus only after surgery to see if there is less discomfort with bowel movements after surgery.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
The purpose of this study is to evaluate if there is a difference in bother related to constipation between a pre-operative versus post-operative start of a bowel regimen for patients undergoing surgery for pelvic organ prolapse This will be a multi-institution, single-blind, randomized control trial utilizing questionnaires and chart review to evaluate effect of pre-operative bowel regimen on post-operative constipation.
- Study team and surgeons will be blinded to group assignments, participants will not be.
- Participants will be randomized after consent is obtained, and at least 1 week prior to planned surgery, via computer-generated blocks in a 1:1 ratio between study group (pre-operative and post-operative use) and control group (post-operative only use) of polyethylene glycol 3350 (PEG)
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- University Hospitals Cleveland Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients assigned female sex at birth undergoing an apical prolapse procedure including: sacrocolpopexy, sacrospinous ligament suspension, uterosacral ligament suspension, or colpocleisis. Planned urogynecologic procedure may include hysterectomy, adnexectomy, colporrhaphy, perineorrhaphy, or treatment of stress urinary incontinence.
- Planning to undergo primary procedure as above via minimally invasive route: vaginal or laparoscopic (including robotic-assisted). Including those that have an unplanned conversion intraoperatively of minimally invasive route to open laparotomy.
Exclusion Criteria:
- Diagnosis of irritable bowel syndrome, inflammatory bowel disease, slow transit constipation, obstructed defecation, or symptomatic constipation at time of study screening and recruitment. (Slow transit constipation and obstructed defecation defined as per American Gastroenterological Association 2013 constipation statement. Symptomatic constipation defined as any of the following: Bristol Stool Scale score of 1 or 2, PAC-SYM score greater than 1.0, self-reported 2 or less bowel movements per week.)
- Current use of pharmacologic laxative agent ≥1x/week (prescription or OTC) for the treatment of constipation symptoms
- Allergy or intolerance to polyethylene glycol 3350
- Planning to undergo surgery via laparotomy
- Scheduled for any concurrent non-urogynecologic procedure, ex abdominoplasty
- History of large bowel resection, surgical treatment of constipation, or anal sphincter surgery
- History of sacral neuromodulation
- Current or prior radiation therapy to the abdomen or pelvis
- Current or prior diagnosis of malignancy
- Unable to provide informed consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Pre-operative
Participants will be instructed to take 17 grams of powder Polyethylene glycol 3350 (PEG) every day starting 3 days prior to scheduled surgery date and continue to take 17 grams of PEG every day for 7 days following the day of surgery. Participants will be allowed to titrate up or down the amount of PEG used as needed and instructed to record all doses of PEG used. |
*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
Andre navne:
|
|
Aktiv komparator: Post-operative
Participants will be instructed to take 17 grams of powder PEG* every day for 7 days starting the day of surgery. Participants will be allowed to titrate up or down the amount of PEG used as needed and instructed to record all doses of PEG used. |
*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
PAC-SYM
Tidsramme: Pre-operative, 1 week post-operative, 2 weeks post-operative
|
Patient assessment of constipation symptoms (PAC-SYM) is a validated 12-item questionnaire with reported average score 0-4. Higher scores indicate more constipation symptoms |
Pre-operative, 1 week post-operative, 2 weeks post-operative
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
PAC-QOL: Patient Assessment of Constipation Quality of Life Measure
Tidsramme: 2 weeks post-operative
|
PAC-QOL is a 28-item questionnaire with scores averaged ranging from 0-4 without units. Higher scores signify worse constipation symptoms. |
2 weeks post-operative
|
|
Time to First Bowel Movement
Tidsramme: 1 week post-operative
|
after surgery in approximate days |
1 week post-operative
|
|
Doses of PEG Used
Tidsramme: 1 week post-operative, 2 weeks post-operative
|
polyethylene glycol 3350 (PEG) doses of 17 grams powder mixed in 8oz of liquid |
1 week post-operative, 2 weeks post-operative
|
|
Number of Participants With Rescue Laxative Use
Tidsramme: 1 week post-operative, 2 weeks post-operative
|
Use of additional laxatives or enemas |
1 week post-operative, 2 weeks post-operative
|
|
Satisfaction With Pain After Surgery
Tidsramme: 1 week post-operative
|
Satisfaction with pain after surgery, 0-10 Likert scale (0=not at all satisfied, 10= completely satisfied) |
1 week post-operative
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: David Sheyn, MD, University Hospitals Cleveland Medical Center
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STUDY20231417
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .